LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, […]readmore
Tags : Marinomed Biotech
Shots: Marinomed to receive $2M up front & is eligible to receive milestones upon achievement of development, regulatory & commercial milestones along with royalties on sales of Budesolv in Greater […]readmore